{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:01:30Z","timestamp":1790650890218,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06595-5","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:34:53Z","timestamp":1758267293000},"page":"4649-4660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013\u20132022 in Finland"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-2847","authenticated-orcid":false,"given":"Juha","family":"Ranti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-9455","authenticated-orcid":false,"given":"Sanaz","family":"Jamalzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9564-3966","authenticated-orcid":false,"given":"Eleonora","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5750-6120","authenticated-orcid":false,"given":"Johanna","family":"Vikkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-5816","authenticated-orcid":false,"given":"Essi","family":"Havula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9370-2569","authenticated-orcid":false,"given":"Sari","family":"Luopaj\u00e4rvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-9120","authenticated-orcid":false,"given":"Vesa","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"6595_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M (2023) Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA 329:918","journal-title":"JAMA"},{"key":"6595_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524\u20131537","journal-title":"Lancet"},{"key":"6595_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E et al (2021) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:23\u201333","journal-title":"Ann Oncol"},{"key":"6595_CR4","unstructured":"Cancer registry F (2023) Cancer statistics. Sy\u00f6p\u00e4rekisteri, https:\/\/cancerregistry.fi\/statistics\/cancer-statistics\/\u00a0Accessed 22 May 2023"},{"key":"6595_CR5","unstructured":"Sepp\u00e4 K, Tanskanen T, Heikkinen S et al (2023) Sy\u00f6p\u00e4 2021. Tilastoraportti Suomen sy\u00f6p\u00e4tilanteesta (eg. Cancer 2021. Statistical Report on Finnish Cancer Status). Suomen Sy\u00f6p\u00e4yhdistys. https:\/\/syoparekisteri.fi\/assets\/files\/2023\/05\/Syopa_2021_final_31052023.pdf"},{"key":"6595_CR6","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840\u20131847","journal-title":"Blood"},{"key":"6595_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848\u20131854","journal-title":"Blood"},{"key":"6595_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000533704","volume":"147","author":"S Kang","year":"2024","unstructured":"Kang S, Ahn IE (2024) Prognostic markers in the era of targeted therapies. Acta Haematol 147:33\u201346","journal-title":"Acta Haematol"},{"key":"6595_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M et al (2019) Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 133:1205\u20131216","journal-title":"Blood"},{"key":"6595_CR10","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760","journal-title":"Blood"},{"key":"6595_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"An international prognostic","year":"2016","unstructured":"An international prognostic (2016) Index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17:779\u2013790","journal-title":"Lancet Oncol"},{"key":"6595_CR12","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96:1679\u20131705","journal-title":"Am J Hematol"},{"key":"6595_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU et al (2024) Esmo clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol 35:762\u2013768","journal-title":"Ann Oncol"},{"key":"6595_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/PPO.0000000000000407","volume":"25","author":"P Islam","year":"2019","unstructured":"Islam P, Mato AR (2019) Real-World evidence for chronic lymphocytic leukemia in the era of targeted therapies. Cancer J 25:442\u2013448","journal-title":"Cancer J"},{"key":"6595_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.13273","volume":"103","author":"V Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m V, Hakkarainen KM, Meht\u00e4l\u00e4 J et al (2019) Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time. Eur J Haematol 103:190\u2013199","journal-title":"Eur J Haematol"},{"key":"6595_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jha2.322","volume":"3","author":"J Ranti","year":"2022","unstructured":"Ranti J, Perkonoja K, Kauko T et al (2022) Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. eJHaem 3:291\u2013300","journal-title":"eJHaem"},{"key":"6595_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682","journal-title":"Am J Epidemiol"},{"key":"6595_CR18","volume-title":"R: A Language and environment for statistical computing","author":"RC Team","year":"2022","unstructured":"Team RC (2022) R: A Language and environment for statistical computing. Austria: R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org\/"},{"key":"6595_CR19","unstructured":"M\u00e4klin S (2017) Terveyden- ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2017. 55"},{"key":"6595_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3324\/haematol.2018.200204","volume":"104","author":"SE Sylvan","year":"2019","unstructured":"Sylvan SE, Asklid A, Johansson H et al (2019) First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica 104:797\u2013804","journal-title":"Haematologica"},{"key":"6595_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Sig Transduct Target Ther 6:201","journal-title":"Sig Transduct Target Ther"},{"key":"6595_CR22","doi-asserted-by":"publisher","first-page":"e70015","DOI":"10.1002\/hem3.70015","volume":"8","author":"L Van Der Straten","year":"2024","unstructured":"Van Der Straten L, Levin M, Dinnessen MAW et al (2024) Causes of death among patients diagnosed with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1996\u20132020. HemaSphere 8:e70015","journal-title":"HemaSphere"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06595-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:03Z","timestamp":1761283803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06595-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06595-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Finnish Social and Health data permit authority Findata (THL\/4633).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"According to the Finnish Act on Secondary use of health and social data (552\/2019), no patient consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"SJ, EH, and JV are employees of Medaffcon Oy. EM is employed by Johnson & Johnson. VL has received honoraria from AbbVie, AstraZeneca, Johnson & Johnson, SL from Abbvie and Johnson & Johnson, and JR from AbbVie, Astra-Zeneca, Beigene and Johnson & Johnson. Medaffcon provided support for planning the study, analyzing the data and interpretation of the results, drafting the manuscript, and medical writing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}